This compound is primarily utilized in the development of treatments for type 2 diabetes. It functions as a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, which helps in reducing blood glucose levels by promoting the excretion of glucose through urine. Its application is significant in managing hyperglycemia in diabetic patients, offering a therapeutic approach that is independent of insulin. Additionally, it has been explored for its potential benefits in improving cardiovascular outcomes and reducing the risk of heart failure in diabetic individuals. The compound’s efficacy and safety profile make it a valuable candidate in the ongoing research and development of diabetes management therapies.